Atara Biotherapeutics (NASDAQ:ATRA) Shares Set to Reverse Split on Thursday, June 20th

Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s stock is going to reverse split before the market opens on Thursday, June 20th. The 1-25 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, June 20th.

Atara Biotherapeutics Trading Down 16.9 %

ATRA stock opened at $0.42 on Tuesday. The company has a market capitalization of $51.12 million, a P/E ratio of -0.20 and a beta of 0.54. Atara Biotherapeutics has a twelve month low of $0.20 and a twelve month high of $2.54. The business has a 50 day simple moving average of $0.63 and a 200-day simple moving average of $0.67.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.14. The business had revenue of $27.36 million during the quarter, compared to the consensus estimate of $27.00 million. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 671.70%. Research analysts predict that Atara Biotherapeutics will post -0.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ATRA shares. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd. StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Insider Buying and Selling

In other Atara Biotherapeutics news, EVP Anhco Nguyen sold 42,899 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $0.62, for a total value of $26,597.38. Following the completion of the sale, the executive vice president now owns 898,498 shares of the company’s stock, valued at $557,068.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 81,506 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $0.62, for a total value of $50,533.72. Following the completion of the sale, the chief executive officer now owns 1,829,146 shares of the company’s stock, valued at $1,134,070.52. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Anhco Nguyen sold 42,899 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total value of $26,597.38. Following the completion of the sale, the executive vice president now directly owns 898,498 shares of the company’s stock, valued at approximately $557,068.76. The disclosure for this sale can be found here. Insiders sold a total of 153,053 shares of company stock valued at $94,893 over the last three months. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Staley Capital Advisers Inc. increased its position in shares of Atara Biotherapeutics by 33.3% in the third quarter. Staley Capital Advisers Inc. now owns 1,000,000 shares of the biotechnology company’s stock valued at $1,480,000 after buying an additional 250,000 shares in the last quarter. 683 Capital Management LLC increased its position in shares of Atara Biotherapeutics by 20.0% in the third quarter. 683 Capital Management LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $1,776,000 after buying an additional 200,000 shares in the last quarter. Redmile Group LLC increased its position in shares of Atara Biotherapeutics by 3.8% in the third quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after buying an additional 232,690 shares in the last quarter. Josh Arnold Investment Consultant LLC increased its position in shares of Atara Biotherapeutics by 17.6% in the third quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30,000 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in shares of Atara Biotherapeutics by 368.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 164,206 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.